NCT05008913View on ClinicalTrials.gov

Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib

PHASE1TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

November 16, 2021

Study Completion Date

November 16, 2021

Conditions

Advanced Solid Tumors

Interventions

DRUG

[14C]Adavosertib

Patients will receive a single administration of \[14C\]Adavosertib as an oral solution on Day 1.

Trial Locations (1)

M20 4BX

Research Site, Manchester

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY

NCT05008913 - Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib | Biotech Hunter | Biotech Hunter